182 related articles for article (PubMed ID: 20467223)
1. [Severe bortezomib-induced peripheral neuropathy in a patient with multiple myeloma].
Sanada Y; Nakazato T; Suzuki K; Mihara A; Aisa Y; Iwabuchi M; Kakimoto T
Rinsho Ketsueki; 2010 Apr; 51(4):264-9. PubMed ID: 20467223
[TBL] [Abstract][Full Text] [Related]
2. Neurological monitoring reduces the incidence of bortezomib-induced peripheral neuropathy in multiple myeloma patients.
Velasco R; Petit J; Clapés V; Verdú E; Navarro X; Bruna J
J Peripher Nerv Syst; 2010 Mar; 15(1):17-25. PubMed ID: 20433602
[TBL] [Abstract][Full Text] [Related]
3. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
4. [Aggravated post-herpetic neuralgia due to bortezomib].
Kirizume K; Imataki O; Shintani T; Fujihara S; Waki F; Ohue Y; Ohnishi H
Rinsho Ketsueki; 2008 May; 49(5):331-4. PubMed ID: 18572810
[TBL] [Abstract][Full Text] [Related]
5. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
Richardson PG; Briemberg H; Jagannath S; Wen PY; Barlogie B; Berenson J; Singhal S; Siegel DS; Irwin D; Schuster M; Srkalovic G; Alexanian R; Rajkumar SV; Limentani S; Alsina M; Orlowski RZ; Najarian K; Esseltine D; Anderson KC; Amato AA
J Clin Oncol; 2006 Jul; 24(19):3113-20. PubMed ID: 16754936
[TBL] [Abstract][Full Text] [Related]
6. [Development of an extramedullary plasmacytoma despite disappearing M protein in multiple myeloma by bortezomib treatment].
Koiso H; Tahara K; Osaki Y; Mawatari M; Sekigami T; Yokohama A; Saitoh T; Uchiumi H; Handa H; Tsukamoto N; Karasawa M; Nojima Y; Murakami H
Rinsho Ketsueki; 2009 Feb; 50(2):78-82. PubMed ID: 19265298
[TBL] [Abstract][Full Text] [Related]
7. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib: new indication. Second-line treatment of myeloma: limited efficacy, major risks.
Prescrire Int; 2006 Jun; 15(83):98-100. PubMed ID: 16764098
[TBL] [Abstract][Full Text] [Related]
9. Role of a pre-existing neuropathy on the course of bortezomib-induced peripheral neurotoxicity.
Lanzani F; Mattavelli L; Frigeni B; Rossini F; Cammarota S; Petrò D; Jann S; Cavaletti G
J Peripher Nerv Syst; 2008 Dec; 13(4):267-74. PubMed ID: 19192066
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
Corso A; Mangiacavalli S; Varettoni M; Pascutto C; Zappasodi P; Lazzarino M
Leuk Res; 2010 Apr; 34(4):471-4. PubMed ID: 19674790
[TBL] [Abstract][Full Text] [Related]
12. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide.
Musto P; Falcone A; Sanpaolo G; Guglielmelli T; Zambello R; Balleari E; Catalano L; Spriano M; Cavallo F; La Sala A; Mantuano S; Nobile M; Melillo L; Scalzulli PR; Dell'Olio M; Bodenizza C; Greco MM; Carella AM; Merla E; Carella AM; Boccadoro M; Cascavilla N; Palumbo A
Leuk Res; 2006 Mar; 30(3):283-5. PubMed ID: 16111749
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.
Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M
J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187
[TBL] [Abstract][Full Text] [Related]
15. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
Richardson PG; Sonneveld P; Schuster MW; Stadtmauer EA; Facon T; Harousseau JL; Ben-Yehuda D; Lonial S; Goldschmidt H; Reece D; Bladé J; Boccadoro M; Cavenagh JD; Boral AL; Esseltine DL; Wen PY; Amato AA; Anderson KC; San Miguel J
Br J Haematol; 2009 Mar; 144(6):895-903. PubMed ID: 19170677
[TBL] [Abstract][Full Text] [Related]
16. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
17. Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma.
Hsiao SC; Wang MC; Chang H; Pei SN
Ann Pharmacother; 2010 Mar; 44(3):587-9. PubMed ID: 20150504
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
Rosiñol L; Montoto S; Cibeira MT; Bladé J
Arch Intern Med; 2005 Feb; 165(4):464-5. PubMed ID: 15738379
[TBL] [Abstract][Full Text] [Related]
19. [Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma].
Arai A; Oshikawa G; Kurosu T; Miki T; Tohda S; Koyama T; Murakami N; Miura O
Rinsho Ketsueki; 2006 Aug; 47(8):777-80. PubMed ID: 16986718
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study.
Uy GL; Goyal SD; Fisher NM; Oza AY; Tomasson MH; Stockerl-Goldstein K; DiPersio JF; Vij R
Bone Marrow Transplant; 2009 May; 43(10):793-800. PubMed ID: 19029964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]